Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Higher FOBT (faecal occult blood test) test reimbursement "dependent on specificity"

This article was originally published in Clinica

Executive Summary

Medicare's open experimentation with cost as one of the factors in making a national coverage determination is so far setting a high bar for manufacturers. A cost-effectiveness study by the Agency for Healthcare Research & Quality (AHRQ) has concluded that a new version of the faecal occult blood test - IFOBT - designed to detect blood in the stool is a cost-effective intervention for reducing colorectal cancer incidence.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT063480

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel